Discover RINVOQ, a once-daily medication for active psoriatic arthritis (PsA). See full Prescribing & Safety Information, and Boxed Warning.
Discover RINVOQ, a once-daily medication for active psoriatic arthritis (PsA). See full Prescribing & Safety Information, and Boxed Warning.
Background Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. Ixekizumab (IXE), a monoclonal high affinity antibody that selectively targets interleukin-17A, has improved disease activity and ...
In patients with active psoriatic arthritis (PsA) who had an inadequate response to tumour necrosis factor inhibitors (TNFi), IXE was superior to placebo (PBO) in improving the signs and symptoms of PsA after 24 weeks of treatment (SPIRIT-P2; NCT02349295).1Objectives The objective of this ...
with active PsA, while data on common efficacy endpoints were similar in these pediatric PsO patients with active PsA. “The approval of STELARA for use in children six years of age and older with active psoriatic arthritis, which follows t...
Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States. Journal of Managed Care and Specialty Pharmacy : 21 Apr 2020. Available from: URL: https://doi.org/10.18553/jmcp.2020.19319 Download references Rights and permissions Reprints and ...
AbbVie Inc. ABBV announced that the FDA has approved its JAK inhibitor, Rinvoq (upadacitinib) for a new indication. The drug is now approved for the treatment of adults with active psoriatic arthritis (PsA) who has had an inadequate response or intoleran
Background Dactylitis and enthesitis are common disabling manifestations of psoriatic arthritis (PsA) that have been reported according to multiple methods of assessment. Several measures of dactylitis and enthesitis were utilized in the phase 3 FUTURE 2 secukinumab study (NCT01752634)1 and are reporte...
Psoriatic arthritis (PsA) is a chronic inflammatory, progressive, destructive disease that results in deformities, impaired physical function, and decreased quality of life [1]. Biologic disease-modifying antirheumatic drugs (bDMARDs) have demonstrated efficacy in treating patients with PsA. bDMARDs ar...
Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiographic progression in psoriatic arthritis (PsA). Methods We conducted preplanned integrated analyses of combined radiographic data from PSUMMIT-1 and PSUMMIT-2 phase 3, randomised, controlled trials. Patients had...